Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame
Executive Summary
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.